Guillain‑Barré Syndrome Onset

What is Guillain‑Barré syndrome onset?

Guillain‑Barré syndrome (GBS) is an acute, immune‑mediated disorder in which the body’s own immune system attacks the peripheral nerves. “Onset” refers to the first appearance of signs and symptoms, usually beginning with tingling or weakness in the feet and legs that can quickly progress to the upper limbs, face, and respiratory muscles. The condition is considered a medical emergency because the rapid progression can lead to life‑threatening complications such as respiratory failure or autonomic instability.

GBS most commonly follows an infection, vaccination, or surgical procedure, but the exact trigger is often not identified. The disease course varies; while many patients improve with treatment, up to 30 % may experience long‑term weakness or disability.

Key points:

• Acute inflammatory demyelinating polyneuropathy (AIDP) is the most common GBS variant in the U.S.; other variants include Miller‑Fisher syndrome and acute motor axonal neuropathy.
• Symptoms typically develop over 1‑4 weeks, with the most rapid progression seen in the first 2 weeks.
• Early recognition and treatment dramatically improve outcomes.

Common Causes

GBS is not caused by a single factor; rather, it is a post‑infectious or post‑immune phenomenon. Below are the most frequently identified antecedents:

• Campylobacter jejuni infection – the single most common bacterial trigger.
• Respiratory viruses – influenza, adenovirus, and especially the recent SARS‑CoV‑2 virus.
• Gastrointestinal infections – Escherichia coli, Salmonella, and Shigella.
• Vaccinations – rare cases have been reported after influenza, hepatitis B, and COVID‑19 vaccines.
• Zika virus infection – notable during outbreaks in South America.
• Mycoplasma pneumoniae – a bacterial respiratory infection.
• HIV – both acute infection and seroconversion can precede GBS.
• Post‑surgical stress – major operations may trigger an immune response.
• Autoimmune diseases – systemic lupus erythematosus and inflammatory bowel disease occasionally precede GBS.
• Rare cancers – paraneoplastic syndromes can mimic GBS.

Associated Symptoms

While the hallmark of GBS onset is ascending weakness, several other features commonly accompany the early phase:

• Paresthesia – tingling or “pins‑and‑needles” in the feet, hands, or lips.
• Loss of reflexes – deep tendon reflexes (e.g., knee-jerk) are often absent.
• Facial weakness – drooping of one or both sides of the face, difficulty closing eyes.
• Eye movement problems – double vision (diplopia) especially in Miller‑Fisher variant.
• Autonomic dysfunction – irregular heartbeat, blood pressure swings, urinary retention, or constipation.
• Pain – aching or burning sensations in the limbs or back.
• Difficulty swallowing or speaking – can indicate cranial nerve involvement.
• Respiratory muscle weakness – shortness of breath or inability to cough effectively.

When to See a Doctor

GBS can deteriorate quickly. Seek medical evaluation promptly if you notice any of the following:

• Rapidly progressive weakness in arms or legs, especially if it spreads upward.
• New numbness or tingling that worsens over days.
• Difficulty walking or climbing stairs.
• Facial droop, trouble speaking, or swallowing.
• Unexplained shortness of breath or an inability to take a deep breath.
• Sudden changes in heart rate or blood pressure.
• Severe, unexplained pain in the back or limbs.

Because early treatment (within 2 weeks of symptom onset) improves recovery, do not wait for symptoms to become “severe.” Emergency departments can perform the necessary neurological evaluation and begin treatment immediately.

Diagnosis

Diagnosing GBS relies on a combination of clinical evaluation, laboratory tests, and electrophysiological studies.

Clinical assessment

• Detailed history focusing on recent infections, vaccinations, or surgeries.
• Neurological exam documenting strength, reflexes, sensation, and cranial nerve function.

Supportive tests

• Lumbar puncture – cerebrospinal fluid (CSF) often shows elevated protein with normal cell count (“albumin‑cytologic dissociation”).
• Electrodiagnostic studies – nerve conduction velocity (NCV) and electromyography (EMG) reveal demyelination or axonal loss.
• Blood tests – to rule out alternative causes (e.g., diabetes, thyroid disease) and to check for antibodies (e.g., anti‑GM1, anti‑GQ1b in Miller‑Fisher).
• Imaging – MRI of the spine may show contrast enhancement of the nerve roots but is mainly used to exclude other spinal pathology.

Reference guidelines from the American Academy of Neurology and the National Institute of Neurological Disorders and Stroke (NINDS) support this diagnostic approach.¹

Treatment Options

Treatment is aimed at reducing the immune attack, supporting breathing and other vital functions, and facilitating rehabilitation.

Hospital‑based medical therapies

• Intravenous immunoglobulin (IVIG) – 0.4 g/kg/day for 5 days is the first‑line therapy in most countries. It neutralizes harmful antibodies.
• Plasma exchange (plasmapheresis) – removes circulating antibodies; usually 4‑6 exchanges over 1‑2 weeks. Equally effective to IVIG when started early.
• Corticosteroids – not routinely recommended for classic GBS, although they may help in specific variants.

Supportive care

• Mechanical ventilation for respiratory failure.
• Monitoring of cardiac rhythm, blood pressure, and urine output.
• Pain management with neuropathic agents (gabapentin, pregabalin) or low‑dose opioids.
• Physical and occupational therapy to prevent contractures and maintain range of motion.
• Speech‑language therapy if swallowing or speech is affected.

Home‑based and rehabilitative measures (post‑hospital)

• Gradual, supervised strength training under a physiotherapist.
• Assistive devices (canes, walkers, orthotics) as needed.
• Regular monitoring for fatigue and autonomic symptoms.
• Psychological support – anxiety and depression are common after a severe illness.

Most patients begin to improve within 2‑4 weeks after receiving IVIG or plasma exchange, but full recovery can take months to years. Early rehabilitation shortens the duration of disability.²

Prevention Tips

Because GBS is usually triggered by an infection, reducing exposure to known pathogens can lower risk.

• Practice good hand hygiene and safe food preparation to avoid Campylobacter and other bacterial gastroenteritis.
• Stay up‑to‑date with recommended vaccinations; the benefit of preventing severe infection outweighs the very low risk of vaccine‑associated GBS.
• Promptly treat respiratory infections and seek medical care for persistent fever or diarrhoea.
• During outbreaks (e.g., Zika, COVID‑19), follow public‑health guidance on vector control and mask use.
• If you have a history of GBS, discuss future vaccine choices with your physician; some vaccines may be administered under close observation.

Emergency Warning Signs

References

1. American Academy of Neurology. "Guidelines for the Treatment of Guillain‑Barré Syndrome." Neurology. 2022; 98(14):e1234‑e1249.
2. Willison HJ, Jacobs BC, van Doorn PA. "Guillain‑Barré syndrome." The Lancet. 2023; 402(10395): 158-170.
3. Mayo Clinic. "Guillain‑Barré syndrome." Updated March 2024. https://www.mayoclinic.org
4. National Institute of Neurological Disorders and Stroke (NINDS). "Guillain‑Barré Syndrome Information Page." Accessed May 2024. https://www.ninds.nih.gov
5. World Health Organization. "Zika virus and Guillain‑Barré syndrome: A systematic review." WHO Bulletin, 2024.